A Randomized, Double-blinded, Placebo-controlled, Parallel, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HY209 Gel for Patients With Atopic Dermatitis
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Taurodeoxycholic-acid (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Shaperon
- 27 Jan 2021 Status changed from recruiting to completed.
- 31 Aug 2020 New trial record